文献速递重症综合管理与镇静镇痛儿科与产科急症

劳拉西泮联合氟哌啶醇对比单用氟哌啶醇治疗接受姑息治疗的晚期癌症患者激越性谵妄:一项随机临床试验

Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01
一句话结论晚期癌症激越性谵妄患者中,氟哌啶醇基础上加用劳拉西泮较单用氟哌啶醇在8小时时激越评分下降更显著,但需进一步研究评估普适性与不良反应。

这项单中心、双盲、平行组随机临床试验在MD Anderson癌症中心急性姑息治疗病房纳入93例晚期癌症且已规律使用氟哌啶醇仍存在激越性谵妄的患者。干预为在激越发作时静脉给予劳拉西泮3 mg(n=47)或安慰剂(n=43),同时均静脉给予氟哌啶醇2 mg。主要终点为基线至给药后8小时Richmond激越-镇静量表(RASS)评分变化。结果显示劳拉西泮+氟哌啶醇组RASS评分下降4.1分,显著大于安慰剂+氟哌啶醇组的2.3分(平均差-1.9分,95%CI -2.8至-0.9,P<.001),且补救神经阻滞剂用量更少、照料者与护士评价的舒适度更高。作者结论认为该初步试验中加用劳拉西泮可更显著改善激越,但需进一步研究评估普适性与不良反应。

要点

  • 晚期癌症激越性谵妄患者已规律使用氟哌啶醇仍激越时,发作时加用静脉劳拉西泮3 mg较安慰剂在8小时RASS评分下降更显著(-4.1分 vs -2.3分,平均差-1.9分,95%CI -2.8至-0.9,P<.001)。
  • 劳拉西泮+氟哌啶醇组补救神经阻滞剂中位用量2.0 mg,低于安慰剂+氟哌啶醇组的4.0 mg(中位差-1.0 mg,95%CI -2.0至0,P=.009)。
  • 盲法照料者评价舒适的比例劳拉西泮+氟哌啶醇组84% vs 安慰剂+氟哌啶醇组37%(平均差47%,95%CI 14%至73%,P=.007);护士评价分别为77% vs 30%(平均差47%,95%CI 17%至71%,P=.005)。
  • 两组谵妄相关痛苦与生存无显著差异;最常见不良反应为运动减少,劳拉西泮+氟哌啶醇组3例(19%),安慰剂+氟哌啶醇组4例(27%)。
  • 作者结论认为这是初步试验,加用劳拉西泮可更显著降低8小时激越,但需进一步研究评估普适性与不良反应。

适用人群与场景

  • 晚期癌症合并激越性谵妄、且已规律使用氟哌啶醇仍存在激越的住院患者,场景为急性姑息治疗病房。

诊断标准与关键阈值

  • 激越性谵妄诊断依据原文未详述;主要终点采用Richmond激越-镇静量表(RASS),评分范围-5(不可唤醒)至4(非常激越或好斗)。

处置流程与药物剂量

  • 激越发作时在氟哌啶醇2 mg静脉给药基础上,加用劳拉西泮3 mg静脉给药或安慰剂。

研究设计与关键结果

  • 单中心、双盲、平行组随机临床试验,纳入93例(随机分组90例分析),平均年龄62岁,女性42例(47%),58例(64%)接受了研究药物,52例(90%)完成试验。
  • 主要终点:劳拉西泮+氟哌啶醇组8小时RASS评分下降4.1分,安慰剂+氟哌啶醇组下降2.3分,平均差-1.9分(95%CI -2.8至-0.9),P<.001。
  • 补救神经阻滞剂中位用量:劳拉西泮+氟哌啶醇组2.0 mg vs 安慰剂+氟哌啶醇组4.0 mg,中位差-1.0 mg(95%CI -2.0至0),P=.009。
  • 盲法照料者评价舒适:劳拉西泮+氟哌啶醇组84% vs 安慰剂+氟哌啶醇组37%,平均差47%(95%CI 14%至73%),P=.007;护士评价:77% vs 30%,平均差47%(95%CI 17%至71%),P=.005。
  • 谵妄相关痛苦与生存两组无显著差异;最常见不良反应为运动减少,劳拉西泮+氟哌啶醇组3例(19%),安慰剂+氟哌啶醇组4例(27%)。

证据类型、等级与局限

  • 证据类型:单中心、双盲、平行组随机临床试验(初步试验)。
  • 局限:作者指出这是初步试验,需进一步研究评估普适性与不良反应。

对床旁实践的改变

  • 对于晚期癌症激越性谵妄且已规律使用氟哌啶醇仍激越的住院患者,作者认为在氟哌啶醇基础上加用劳拉西泮可更显著降低8小时激越,但需进一步研究评估普适性与不良反应。

指南或共识出处

  • 临床试验注册号:clinicaltrials.gov NCT01949662。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The use of benzodiazepines to control agitation in delirium in the last days of life is controversial.

OBJECTIVE: To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer.

DESIGN, SETTING, AND PARTICIPANTS: Single-center, double-blind, parallel-group, randomized clinical trial conducted at an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled haloperidol from February 11, 2014, to June 30, 2016, with data collection completed in October 2016.

INTERVENTIONS: Lorazepam (3 mg) intravenously (n = 47) or placebo (n = 43) in addition to haloperidol (2 mg) intravenously upon the onset of an agitation episode.

MAIN OUTCOMES AND MEASURES: The primary outcome was change in Richmond Agitation-Sedation Scale (RASS) score (range, -5 [unarousable] to 4 [very agitated or combative]) from baseline to 8 hours after treatment administration. Secondary end points were rescue neuroleptic use, delirium recall, comfort (perceived by caregivers and nurses), communication capacity, delirium severity, adverse effects, discharge outcomes, and overall survival.

RESULTS: Among 90 randomized patients (mean age, 62 years; women, 42 [47%]), 58 (64%) received the study medication and 52 (90%) completed the trial. Lorazepam + haloperidol resulted in a significantly greater reduction of RASS score at 8 hours (-4.1 points) than placebo + haloperidol (-2.3 points) (mean difference, -1.9 points [95% CI, -2.8 to -0.9]; P < .001). The lorazepam + haloperidol group required less median rescue neuroleptics (2.0 mg) than the placebo + haloperidol group (4.0 mg) (median difference, -1.0 mg [95% CI, -2.0 to 0]; P = .009) and was perceived to be more comfortable by both blinded caregivers and nurses (caregivers: 84% for the lorazepam + haloperidol group vs 37% for the placebo + haloperidol group; mean difference, 47% [95% CI, 14% to 73%], P = .007; nurses: 77% for the lorazepam + haloperidol group vs 30% for the placebo + haloperidol group; mean difference, 47% [95% CI, 17% to 71%], P = .005). No significant between-group differences were found in delirium-related distress and survival. The most common adverse effect was hypokinesia (3 patients in the lorazepam + haloperidol group [19%] and 4 patients in the placebo + haloperidol group [27%]).

CONCLUSIONS AND RELEVANCE: In this preliminary trial of hospitalized patients with agitated delirium in the setting of advanced cancer, the addition of lorazepam to haloperidol compared with haloperidol alone resulted in a significantly greater reduction in agitation at 8 hours. Further research is needed to assess generalizability and adverse effects.

TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01949662.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. JAMA. 2017. PMID: 28975307. doi:10.1001/jama.2017.11468

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。